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ABSTRACT
This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase 
inhibitors and resistance with an emphasis on raltegravir (RAL), the fi rst integrase inhibitor licensed 
to treat HIV-1 infection.
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INTRODUCTION
The replication of all retroviruses including the 
Human Immunodefi ciency Virus Type 1 (HIV-1) 
requires three viral enzymes: reverse transcriptase 
(RT), protease (Pr) and integrase (In). The de-
velopment of inhibitors of reverse transcriptase 
and protease and the subsequent introduction 
of combination drug regimens which enhance 
the overall effi cacy and durability of therapy 
revolutionized the treatment of HIV-1 infection 
in the mid 1990’s. As the last of the three essen-
tial HIV-1 enzymes, integrase was considered an 
equally attractive target for antiretroviral drug de-
velopment as protease and reverse transcriptase, 
but it is only a decade later that the fi rst integrase 
inhibitor, raltegravir (RAL, MK-0518) achieved 
regulatory approval, reviewed in Cahn,1 while 
other integrase inhibitors including elvitegravir 
(EVG, GS-9137, JTK303) and soltegravir (S1360) 
are still in clinical development. In this review we 
will provide an overview of the biology and bio-
chemistry of integrase inhibitors and an update 
on our current understanding of resistance to this 
newest class of antiretroviral agents.
The role of integrase in HIV-1 replication
Integrase mediates the irreversible insertion 
or integration of the HIV-1 DNA into the host 
genomic DNA.2-4 Integration is required to 
maintain the HIV-1 genome in the infected cell 
and for the effi cient expression of all viral pro-
teins leading to the generation of new viruses. 
Integrase mediates three highly specifi c and co-
ordinated steps which are required for integra-
tion (Figure 1). Integrase initially assembles at 
specifi c sequences within the long terminal repeat 
Figure 1: Schematic representation of the multi-staged process of integration.
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(LTR) regions at each end of the fully reverse transcribed HIV-1 
DNA. In the context of this complex (termed pre-integration 
complex or PIC), integrase then catalyses the subsequent en-
zymatic reactions, 3’ end processing which removes the termi-
nal 3’ dinucleotide from each end of the viral DNA and strand 
transfer which results in the covalent linkage of the viral DNA 
and the host DNA.5 All integrase inhibitors in clinical develop-
ment to date specifi cally target the strand transfer reaction6-8 
and are thus alternately referred to as either integrase inhibitor 
(INIs) or more specifi cally integrase strand transfer inhibitors 
(InSTIs). In the context of the viral infection process, inhibition 
of integration results in an irreversible block to HIV-1 replica-
tion as the unintegrated viral DNA is subject to metabolism by 
a variety of cellular enzymes (Figure 1). Although most of the 
unintegrated viral DNA is degraded, recombination and repair 
processes in the cell can also generate 1 and 2 LTR circular DNA 
byproducts. These circles were fi rst described with integration 
defective HIV-1 viruses,9,10 but are now a hallmark of the effect 
of integrase inhibitors both in vitro and in vivo.11,12
The biochemistry of integrase inhibitors
Integrase strand transfer inhibitors or InSTIs have minimal ef-
fects on either the assembly of the integrase DNA complex 
or the 3’ end processing reaction. Their selective effect on the 
strand transfer reaction is a direct result of a now well-defi ned 
mechanism of action in which the inhibitor: 1) binds only to 
the specifi c complex between integrase and the viral DNA and 
not to integrase in the absence of the DNA, and 2) interacts with 
the two essential magnesium metal ion cofactors in the inte-
grase active site post assembly.13 All InSTIs therefore have two 
essential components to their chemical structure, a metal bind-
ing pharmacophore which sequesters the active site magnesium 
and a hydrophobic group which interacts with the viral DNA 
as well as the enzyme in the complex. (See model in Figure 2) 
The metal binding portion of these compounds is absolutely 
essential for inhibition while the hydrophobic component of 
the chemical structure is largely responsible for enhancing 
the overall affi nity and specifi city of the inhibitor in the 
integrase DNA complex.14 The recent co-crystallization of 
the Foamy virus integrase DNA complex or intasome with 
both RAL and EVG15 corroborates many of the original 
biochemical observations that led to this model and pro-
vides a structural basis for understanding the breadth of 
antiviral activity that has been observed for InSTIs across 
all HIV-1 subtypes as well as other retroviruses including 
HIV-2 and XMRV.16-22 In the co-crystal structure the gen-
eral architecture and amino acids within the active site of 
the Foamy virus intasome are highly conserved among ret-
roviral integrases, as are the immediate surrounding inter-
actions with InSTIs. 
The striking conservation of the active site interactions in 
the intasome would be consistent with the observation that 
mutations which engender resistance to InSTIs do not appear 
to be present as polymorphisms in the HIV-1 quasispecies at 
baseline in integrase inhibitor naïve patients.23-25 Baseline resist-
ance to RAL has not been detected in several studies including 
an analysis of both B and non-B subtypes. Primary InSTI mu-
tations have also not been detected in InSTI-naïve individuals, 
regardless of exposure to other antiretroviral agents or duration 
of HIV-1 disease. However, naturally occurring InSTI polymor-
phisms are present for integrase as for all HIV-1 proteins, par-
ticularly in patients infected with non-B viruses.19 The clinical 
consequence of integrase polymorphisms on InSTI response 
and resistance remains to be determined but limited data to 
date has suggested no difference in overall clinical response to 
RAL among B-and non-B HIV-1 infections.18 Studies that have 
evaluated in vitro the susceptibility to RAL and EVG using large 
panels of clinical isolates with multiple HIV-1 subtypes have 
also shown that fold changes in the IC50 to these inhibitors are 
below the biological threshold.26 In addition, HIV-1 group O 
and HIV-2 viruses, which show signifi cant heterogeneity in the 
integrase gene compared to group M viruses display similar 
susceptibility to RAL.24 
The common mechanism of action and conserved bind-
ing mode for InSTIs also has important implications for un-
derstanding cross resistance to the class. In principle, resistance 
mutations can either affect interactions between the metal 
binding pharmacophore and magnesium at the integrase ac-
tive site and/or directly affect interactions between the pendant 
groups in the inhibitor and the enzyme and viral DNA.8 Muta-
tions which engender resistance to InSTIs almost always map 
within the integrase active site near the amino acid residues that 
coordinate the essential magnesium cofactors27,15 rather than 
by affecting interactions with the enzyme viral DNA. Given 
the critical nature of the metal cofactors to integrase function, 
these mutations have a deleterious effect on enzymatic activity 
and viral replication. However, these mutations also engender 
signifi cant cross resistance and although different InSTIs have 
distinct resistance mutations there is signifi cant overlap in re-
sistance to many of these inhibitors.28,29 
Figure 2: Model of InSTI interactions in the active site of 
integrase (based on Grobler, Stillmock et al.14).
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InSTI resistance in vitro and in vivo
The development of resistance to structurally diverse InSTIs 
has now been documented both in vitro and in vivo.11, 28, 30-37 
In vitro, the selection of resistance has been shown to require 
multiple passages of HIV-1 in cell culture, likely as a result of 
both the sequential accumulation of mutations as well as the 
reduced fi tness of these mutants.30,31 While diverse InSTIs 
can select different mutations, nearly all of the amino acid 
residues associated with InSTI resistance localize within the 
integrase active site proximal to the amino acid residues in-
volved in coordinating the metal cofactors consistent with a 
common mechanism of a metal sequestration.8 Importantly, 
resistance to InSTIs does not affect susceptibility to other 
antiretroviral agents, including PIs, NNRTIs, RTIs and the 
various classes of entry inhibitors. 
The selection of resistance to early, prototypic integrase 
inhibitors and clinical development candidates has identifi ed 
a variety of genetic pathways which are defi ned by a single 
characteristic or signature resistance mutation.38,39 In clinical 
trials three primary mutational routes conferring high-level 
resistance to RAL have been observed: 1) N155H in combina-
tion with L74M, E92Q or G163R, 2) Q148H/R/K with E138K 
or G140S/A and 3) Y143R/C mutation plus other muta-
tions.40 For RAL, these general patterns have been confi rmed 
in a variety of cohort studies.41,42 For EVG, patients experi-
encing treatment failure also selected viruses with mutations 
at E92Q, E138K, Q148H/R/K, and N155H as well as other 
mutations.32,33 In vitro, other InSTIs have been shown to select 
different mutations including S153Y.27 While the overall mag-
nitude of the effect of any specifi c individual mutation can 
vary for different InSTIs there is considerable overlap between 
the resistance profi les among InSTIs including all three of the 
current clinical candidates (Figure 3).
For RAL, the N155H mutation confers ~10-fold loss of sen-
sitivity, while the Q148H, Q148K, and Q148R mutations confer 
~20 to 40-fold resistance. Among other single amino acid chang-
es tested, only Y143R conferred > 10-fold resistance to RAL. All 
other substitutions (E92Q, T97A, V151I, G140A, G140S) have 
signifi cantly smaller effects (< 4-fold). Because of the frequency 
with which they have been observed both in clinical trials and in 
cohort studies and the observation that each of these mutations 
individually confers a > 10-fold loss of RAL susceptibility, mu-
tations at Y143, Q148, and N155 are considered “primary mu-
tations;” whereas other mutations which confer limited change 
in susceptibility to RAL and are observed almost exclusively in 
the context of these “primary” substitutions are considered to be 
“secondary” mutations. It should be noted however, that there 
may be additional context effects which contribute to resistance 
and the magnitude of the effect of both single and multiple InSTI 
mutations can vary in clinical isolates.
The evolution of secondary mutations in the context of a 
primary mutation has been shown to increase the level of over-
all resistance to RAL both in the context of site directed mu-
tants as well as in clinical isolates40 (Figure 4). The addition of 
L74M, E92Q, T97A, Y143H, E92Q+T97A, V151I, or G163R to 
N155H increases the fold-change IC50 to RAL from approxi-
mately 10-fold (N155H alone) to as much as more than 100-
fold (range: 20 to > 100-fold). The addition of a G140 mutation 
to Q148R or H augments resistance in a surprisingly specifi c 
manner, G140S/Q148R and G140S/Q148H exhibit ~405-fold 
and ~521-fold resistance, respectively. 
Given the highly conserved nature of the amino acid resi-
dues associated with primary resistance to RAL, it is not sur-
prising that viruses with these mutations exhibit reduced repli-
cation capacity (40 to 60% of wild-type) (Figure 4). However, in 
contrast to the observation that secondary mutations generally 
augment the level of resistance to RAL when combined with 
primary mutations, the effect of secondary mutations on the 
replication capacity viruses of viruses with primary InSTI mu-
tations can vary considerably. Although in most cases, second-
ary mutations have either no effect or further reduce replication 
capacity, in the most striking case the addition of the G140S 
secondary mutation to Q148H compensates for the replication 
capacity defects of Q148H (Figure 4). The latter likely accounts 
Figure 3: Resistance and cross resistance among InSTIs (RAL, 
EVG and GS5172). The effect of RAL resistance associated 
mutations (RAMS) as site directed mutations on antiviral 
activity in vitro.
Figure 4: Effects of resistance mutations on RAL activity and 
viral replication capacity as measured in a single cycle HIV-1 
infectivity assay.
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for the observation that both in clinical studies and in surveil-
lance studies, G140S/Q148H is the most frequent combination 
observed in patients failing RAL with bona fi de resistance. 
In patients with virologic failure and RAL resistance, 
viruses with Q148H mutations are fi tter than those with 
N155H mutations.43 Longitudinal genotyping has shown 
that when RAL resistance evolves with the Q148H muta-
tion, the integrase genotype is stable over time even when 
patients are maintained on RAL. In contrast, N155H vi-
ruses are frequently replaced by viruses with Q148H muta-
tions likely present in the quasispecies early on during fail-
ure. The N155H and Q148H mutations have been shown 
to occur on separate viruses in these patients. The ultimate 
emergence of a dominant Q148H population from such 
mixtures demonstrates that in the presence of RAL, Q148H 
variants have a competitive advantage relative to N155H 
mutants due to the signifi cant difference in replication ca-
pacity between these the two pathways.
Though replication capacity may play a role in pathway 
selection the acquisition of InSTI mutations in RAL fail-
ures is mainly driven by selection for higher levels of resist-
ance. After virologic failure, the overall level of resistance 
to RAL tends to increase with time.41 In many patients, 
the number of integrase resistance mutations increases 
with time correlating with higher-level resistance. In other 
patients, switching from the N155H pathway (generally 
lower-level resistance) to the Q148/K/R variants associated 
with higher-level resistance was observed. The replica-
tion capacity of viruses with Q148R or K plus secondary 
mutation(s) is similar to that of viruses with N155H plus 
secondary mutation(s), therefore switching of the popula-
tion in these patients is best explained by selection pressure 
requiring the higher level of resistance. 
Clinical observations: virologic failure and resistance
Several recent studies have shown that a substantial propor-
tion of virological failures in patients on RAL therapy oc-
cur in the absence of InSTI mutations.41,42,44 Even among a 
cohort of highly treatment-experienced subjects failing RAL 
containing regimen, failure with wild-type integrase was 
relatively common (particularly during early failure); how-
ever, InSTI resistance may emerge in subjects who remain 
on RAL in the context of virologic failure. Several reports 
have described evolution of resistance mutations under 
continued RAL pressure in the absence of complete viral 
suppression.39,41 In some early treatment failures, virus pop-
ulations containing N155H alone were observed to switch 
to virus populations with Q148R or H. Additional studies 
have also documented the dynamics of RAL resistance and 
the evolution of N155N/H to Q148H or N155H to Y143R 
in subjects with incomplete viral suppression.45 The obser-
vation of InSTI resistance evolution during virologic failure 
may suggest that remaining on a RAL regimen could mitigate 
future therapeutic options within the InSTI class. However, 
some studies have suggested RAL may have persistent im-
munologic and virologic benefi t even after the development 
of resistance.41 Given the different overall impact on viral 
replication capacity and distinct evolutionary trajectory 
for each resistance pathway, whether to continue RAL in 
patients who have limited options for complete viral sup-
pression remains a challenging question that may depend as 
much on the specifi c InSTI resistance pathway as on the pa-
tient’s specifi c clinical situation. It is interesting to note that 
in the Coronet study where data were collected from mul-
tiple centers throughout Europe, of the three major path-
ways of RAL resistance, N155H and Y143R/C were observed 
in both B and non-B subtypes, while Q148H/R/K was less 
common in non-B subtypes. Further studies are needed to 
determine how the development of RAL resistance through 
different resistance pathways may be inﬂ uenced by genetic 
context and whether these differences will impact the over-
all ability to recycle current integrase inhibitors or inﬂ uence 
response to next generation agents in the class.
SUMMARY
The first integrase inhibitor, RAL, was introduced in 1997 
and is now approved for both treatment experienced and 
treatment naïve patients. A limited number of additional 
integrase inhibitors is now advancing in clinical develop-
ment, and a wide variety of chemically diverse InSTIs has 
been disclosed in the recent patent and scientific literature. 
These inhibitors exhibit a common mechanism which in-
volves binding to the active site magnesium in the inte-
grase DNA complex. Owing to the common manner in 
which InSTIs engage the magnesium within the integrase 
active site, overlapping resistance is observed with many 
compounds in this class and there is substantial cross-re-
sistance among the first generation agents RAL and EVG 
in vitro and in vivo. In HIV-1 infected patients resistance 
to RAL can evolve through multiple independent genetic 
pathways characterized by signature mutations at one of 
three active site residues (S143, N155 and Q148) and the 
stepwise accumulation of secondary mutations which 
lead to high level resistance. Although RAL and InSTIs in 
general are active across diverse HIV-1 subtypes46 and a 
broad range of retroviruses including HIV-2 and XMRV, 
additional work is needed to understand the development 
of resistance in diverse HIV-1 genetic backgrounds and 
context effects which may inﬂ uence the evolution of InSTI 
resistance. Understanding the underlying mechanisms of 
resistance and the recent co-crystallization of RAL and 
EVG with the Foamy virus intasome will be useful for fu-
ture drug development efforts aimed at identifying novel 
InSTIs that can address the emergence of resistance to 
first generation InSTIs in HIV-1 patients. 
Resistance to inhibitors of the human immunodefi ciency virus type 1 integration
517Braz J Infect Dis 2010; 14(5):513-518
REFERENCES
1. Cahn P, Sued O. Raltegravir: a new antiretroviral class for sal-
vage therapy. Lancet 2007; 369:1235-1236.
2. Brown PO. Retroviruses. Cold Spring Harbor Laboratory 
Press: Cold Spring Harbor, New York, 1998.
3. Chiu TK, Davies DR. Structure and function of HIV-1 inte-
grase. Curr Top Med Chem 2004; 4(9):965-77.
4. Craigie R. HIV integrase, a brief overview from chemistry to 
therapeutics. J Biol Chem 2001; 276(26):23213-6.
5. Engelman A, Mizuuchi K, Craigie R. HIV-1 DNA integration: 
mechanism of viral DNA cleavage and DNA strand transfer. 
Cell. 1991; 67(6):1211-1221.
6. Young SD. Inhibition of HIV-1 integrase by small molecules: 
the potential for a new class of AIDS chemotherapeutics. Curr 
Opin Drug Discov Devel 2001; 4(4):402-10.
7. Johnson AA, Marchand C, Pommier Y. HIV-1 integrase inhibi-
tors: a decade of research and two drugs in clinical trial. Curr 
Top Med Chem 2004; 4(10):1059-77.
8. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to 
treat HIV/AIDS. Nat Rev Drug Discov 2005; 4(3):236-248.
9. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. 
HIV-1 replication is controlled at the level of T cell activation 
and proviral integration. Embo J 1990; 9(5):1551-60.
10. Wiskerchen M, Muesing MA. Human immunodefi ciency vi-
rus type 1 integrase: effects of mutations on viral ability to 
integrate, direct viral gene expression from unintegrated viral 
DNA templates, and sustain viral propagation in primary cells. 
J Virol 1995; 69(1):376-86.
11. Hazuda DJ, Felock P, Witmer M et al. Inhibitors of strand 
transfer that prevent integration and inhibit HIV-1 replication 
in cells. Science 2000; 287(5453):646-50.
12. Buzón M, Massanella M, Llibre JM et al. HIV-1 replication and 
immune dynamics are affected by raltegravir intensifi cation of 
HAART-suppressed subjects. Nature Medicine 2010; 16:460-465.
13. Espeseth AS, Felock, P, Wolfe A  et al. HIV-1 integrase in-
hibitors that compete with the target DNA substrate defi ne a 
unique strand transfer conformation for integrase. Proc Natl 
Acad Sci USA 2000; 97(21):11244-9.
14. Grobler JA, Stillmock K, Hu B et al. Diketo acid inhibitor 
mechanism and HIV-1 integrase: implications for metal bind-
ing in the active site of phosphotransferase enzymes. Proc Natl 
Acad Sci USA 2002; 99(10):6661-6.
15. Hare S, Gupta SS, Volkov E, Engelman A, Cherepanov P. Retro-
viral intasome assembly and inhibition of DNA strand trans-
fer. Nature. 2010; 464(7286):232-236.
16. Maignan S, Guilloteau JP, Zhou-Liu Q, Clement-Mella C, 
Mikol V. Crystal structures of the catalytic domain of HIV-1 
integrase free and complexed with its metal cofactor: high level 
of similarity of the active site with other viral integrases. J Mol 
Biol 1998; 282(2):359-68.
17. DamondF, Lariven S, Roquebert B et al. Virological and immu-
nological response to HAART regimen containing integrase in-
hibitors in HIV-2-infected patients. AIDS 2008; 22(5):665-6.
18. Danovich R, Ke Y, Wan H et al. Raltegravir has similar in vitro 
antiviral potency, clinical effi cacy, and resistance patterns in B 
subtype and non-B subtype HIV-1. In: Abstracts of the Sev-
enteenth International AIDS Conference, Mexico City, 2008. 
Abstract TUAA0302. 
19. Garrett N, Xu L, Smit E, Ferns B, El-Gadi S, Anderson J. Ralte-
gravir treatment response in an HIV-2 infected patient: a case 
report. AIDS 2008; 22(9):1091-112.
20. Shimura K, Kodama E, Sakagami Y et al. Broad antiretrovi-
ral activity and resistance profi le of the novel HIV integrase 
inhibitor elvitegravir. (JTK-303/GS-9137). J Virol 2008; 
82(2):764-74.
21. Briz V, Garrido C, Poveda E et al. Raltegravir and etravirine are 
active against HIV type 1 group O. AIDS Res Hum Retrovi-
ruses 2009; 25(2):225-7.
22. Singh I, Gorzynski J, Drobysheva D, Bassit L, Schinazi R. 
Raltegravir is a potent inhibitor of XMRV, a virus implicated 
in prostate cancer and chronic fatigue syndrome. PLoS One 
2010; 5(4):e9948.
23. Fransen S, Gupta S, Paxinos E et al. Natural variation in sus-
ceptibility of patient-derived HIV-1 to an integrase strand 
transfer inhibitor. XV International HIV Drug Resistance 
Workshop: Basic Principles and Clinical Implications; 2006.
24. Myers RE, Pillay D. Analysis of natural sequence variation and 
covariation in human immunodefi ciency virus type-1 inte-
grase. J Virol 2008; 82(18):9228-9235.
25. Low A, Prada N, Topper M et al. Natural polymorphisms of 
human immunodefi ciency virus type 1 integrase and inherent 
susceptibilities to a panel of integrase inhibitors. Antimicrob 
Agents Chemother. 2009; 53(10):4275-4282.
26. Van Baelen K, Van Eygen V, Rondelez E, Stuyver LJ. Clade-
specific HIV-1 integrase polymorphisms do not reduce 
raltegravir and elvitegravir phenotypic susceptibility. AIDS 
2008; 22(14):1877-80.
27. Hazuda DJ, Anthony NJ, Gomez RP et al. From the Cover: A 
naphthyridine carboxamide provides evidence for discordant 
resistance between mechanistically identical inhibitors of HIV-1 
integrase. Proc Natl Acad Sci USA 2004; 101(31):11233-8.
28. Goethals O, Clayton R, Van Ginderen M et al. Resistance muta-
tions in HIV type 1 integrase selected with elvitegravir confer 
reduced susceptibility to a wide range of integrase inhibitors. J 
Virol 2008; 82(21):10366-74.
29. Marinello J, Marchand C, Mott B, Bain A, Thomas CJ, Pom-
mier Y. Comparison of raltegravir and elvitegravir on HIV-1 
integrase catalytic reactions and on a series of drug-resistant 
integrase mutants. Biochemistry 2008; 47(36):9345-54.
30. Fikkert V, Van Maele B, Vercammen J et al. Development of 
resistance against diketo derivatives of human immunodefi -
ciency virus type 1 by progressive accumulation of integrase 
mutations. J Virol 2003; 77(21):11459-70.
31. Fikkert V, Hombrouck A, Van Remoortel B et al. Multiple 
mutations in human immunodefi ciency virus-1 integrase 
confer resistance to the clinical trial drug S-1360. AIDS 2004; 
18(15):2019-28.
32. Jones G, Ledford R, Yu F, Miller MD, et al. Resistance profi le of 
HIV-1 mutants in vitro selected by the HIV-1 integrase inhibi-
tor, GS-9137 (JTK-303). 14th Conference on Retroviruses and 
Opportunistic Infections Los Angeles. 2007.
33. McColl D, Fransen S, Gupta S et al. Resistance and cross-re-
sistance to fi rst generation integrase inhibitors: insights from 
a Phase II study of elvitegravir (GS-9137). XVI International 
HIV Drug Resistance Workshop: Abstract 12. 2007.
34. Ceccherini-Silberstein F, Armenia D, D’Arrigo R et al. Viro-
logical response and resistance in multi-experienced patients 
treated with raltegravir. XVII International HIV Drug Resist-
ance Workshop. Abstract 18. 2008.
35. Garvey EP, Johns BA, Gartland MJ et al. The naphthyridinone 
GSK364735 is a novel, potent human immunodefi ciency vi-
rus type 1 integrase inhibitor and antiretroviral. Antimicrob 
Agents Chemother 2008; 52(3):901-908. 
36. Hombrouck A, Voet A, Van Remoortel B et al. Mutations in 
human immunodefi ciency virus type 1 integrase confer resist-
ance to the naphthyridine L-870,810 and cross-resistance to 
the clinical trial drug GS-9137. Antimicrob Agents Chemother 
2008; 52(6):2069-2078.
Hazuda
518
37. Malet I, Delelis O, Valantin MA et al. Mutations associated 
with failure of raltegravir treatment affect integrase sensi-
tivity to the inhibitor in vitro. Antimicrob Agents Chem-
other 2008; 52(4):1351-1358.
38. Cooper D, Steigbigel R, Gatell J et al. Subgroup and resist-
ance analyses of raltegravir for resistant HIV-1 infection. 
N Engl J Med 2008; 359(4):355-65.
39. Charpentier C, Karmochkine M, Laureillard D et al. Drug re-
sistance profi les for the HIV integrase gene in patients failing 
raltegravir salvage therapy. HIV Med 2008; 9(9):765-70.
40. Fransen S, Gupta S, Danovich R et al. Loss of raltegravir 
susceptibility of HIV-1 is conferred by multiple non-over-
lapping genetic pathways. J. Virol 2009; 83:11440-1446.
41. Hatano H, Lampiris H, Fransen S et al. Evolution of inte-
grase resistance during failure of integrase inhibitor-based 
antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 
54(4):389-93.
42. Geretti A, Fearnhill E, Ceccherini-Silberstein F et al. Prevalence 
and patterns of raltegravir resistance in treated patients in Europe. 
2010 XVIV International HIV Drug Resistance Workshop.
43. Quercia R, Dam E, Perez-Bercoff D, Clavel F. Selective-advan-
tage profi le of Human Immunodefi ciency virus type 1 inte-
grase mutants explains In Vivo evolution of raltegravir resist-
ance genotypes. J.Virol 2009; 83(19):10245-10249. 
44. Soriano V, Garido C, Alverez E et al. Plasma raltegravir expo-
sure inﬂ uences the antiviral activity and selection of resistance 
mutations. 2010 International HIV and Hepatitis Virus Drug 
Resistance Workshop, Dubrovnik, Croatia.
45. Ferns R, Kirk S, Bennett J, et al. The dynamics of appear-
ance and disappearance of HIV-1 integrase mutations dur-
ing and after withdrawal of raltegravir therapy. AIDS 2009; 
23(16):2159-64.
46. Garrido C, Geretti A, Zahonero N et al. Integrase variability 
and susceptibility to HIV integrase inhibitors: impact of sub-
types, antiretroviral experience and duration of HIV infection. 
J Antimicrob Chemother 2010; 65(2):320-6.
Resistance to inhibitors of the human immunodefi ciency virus type 1 integration
